These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
811 related articles for article (PubMed ID: 15748426)
1. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial]. Chen SJ; Chen LJ; Zhou GB Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426 [TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia: from clinic to molecular biology. Chen SJ; Wang ZY; Chen Z Stem Cells; 1995 Jan; 13(1):22-31. PubMed ID: 7719245 [TBL] [Abstract][Full Text] [Related]
3. Retinoic acid and acute promyelocytic leukemia: a model of targetting treatment for human cancer. Chen Z; Chen SJ; Wang ZY C R Acad Sci III; 1994 Dec; 317(12):1135-41. PubMed ID: 7697468 [TBL] [Abstract][Full Text] [Related]
4. The molecular biology of acute promyelocytic leukemia. Slack JL; Gallagher RE Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864 [TBL] [Abstract][Full Text] [Related]
7. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
8. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336 [TBL] [Abstract][Full Text] [Related]
9. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia. Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666 [TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Chen Z; Wang ZY; Chen SJ Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176 [TBL] [Abstract][Full Text] [Related]
11. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML. Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078 [TBL] [Abstract][Full Text] [Related]
12. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Grimwade D; Solomon E Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677 [TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693 [TBL] [Abstract][Full Text] [Related]
14. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858 [TBL] [Abstract][Full Text] [Related]
15. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537 [TBL] [Abstract][Full Text] [Related]
16. [A study on the relationship between morphology and gene heterogeneity in acute promyelocytic leukemia]. Xiong S; Chen Z; Huang W Zhonghua Nei Ke Za Zhi; 1995 Mar; 34(3):165-8. PubMed ID: 7648936 [TBL] [Abstract][Full Text] [Related]
17. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570 [TBL] [Abstract][Full Text] [Related]
18. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688 [TBL] [Abstract][Full Text] [Related]
19. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
20. The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain. Sitterlin D; Tiollais P; Transy C Oncogene; 1997 Mar; 14(9):1067-74. PubMed ID: 9070655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]